Group Ketamine Pilot; Therapist Training Platform’s Seed Round; Durable Response to PAT at 12 Month Follow up

The Trip Report goes through the latest psychedelic news from February 2022. Highlights include Novamind’s ketamine-assisted therapy, Fluence’s $3 million seed round, and reporting on the 12-month Johns Hopkins depression follow-up study.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account
Category Blog / Article
Published in The Trip Report

Companies Featured

Fluence
Fluence is one of the largest training companies offering education for (future) psychedelic therapists, with a focus on ketamine.

Novamind
Novamind has bold plans for building out a psychedelic ecosystem. One that spans from ketamine-assisted psychotherapy and psilocybin retreats to novel clinical trials.

Johns Hopkins University
Johns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.

People Featured

Reid Robison
Reid Robison is CMO at Novamind.

Article Author

Zach Heigney
Zach Heigney is the excellent writer behind the insightful The Trip Report publication.

Paper Featured

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
This 12-month follow-up study (n=24) assessed the efficacy and safety of psilocybin in depressed participants from a previous trial. A durable antidepressant effect was observed with treatment response (⩾50% reduction in GRID-HAMD score from baseline, Cohen d = 2.4) and rate of remission at 75% and 58%, respectively, at 12 months. No serious adverse events related to psilocybin were observed.

0 Comments
Inline Feedbacks
View all comments